Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Novo Nordisk and Nypro Investing $4B in North Carolina

By Pharmaceutical Processing | October 5, 2014

Novo NordiskNovo Nordisk, the pharmaceutical giant behind popular medications Ozempic and Wegovy, has announced plans for a massive $4.1 billion investment in a new manufacturing facility. This development marks the largest single life science investment in North Carolina’s history and signals a significant expansion of the company’s production capabilities in the United States.

  • Location: Johnston County, North Carolina
  • Investment Amount: $4.1 billion
  • Job Creation: 1,000 new jobs with an average salary of $70,000
  • Opening Date: Slated for 2027
  • Purpose: Production of medications for obesity and other chronic illnesses

This new facility is part of Novo Nordisk’s broader strategy to increase production of semaglutide, the key ingredient in their blockbuster drugs Ozempic and Wegovy. North Carolina is now one of only two locations globally where Novo Nordisk manufactures semaglutide.

The investment is expected to provide a significant boost to the local economy, adding to the already thriving biotech industry in the Triangle area. North Carolina’s lower corporate tax rates were cited as a key factor in attracting this substantial investment.

This announcement builds on Novo Nordisk’s existing presence in North Carolina. In 2010, the company, along with Nypro Inc., announced plans to create 241 jobs over four years through a $161 million investment. That expansion included:

  • 85 new jobs at Novo Nordisk’s Clayton plant for increased production of an insulin delivery device.
  • Additional hiring at Nypro’s Asheville facility for manufacturing and assembly of the device
  • $600,000 in grants from the governor’s One North Carolina Fund
  • Potential for an additional $840,000 in incentives for Novo Nordisk, contingent on meeting job creation and investment targets

The latest $4.1 billion investment represents a significant scaling up of Novo Nordisk’s commitment to North Carolina, reflecting the growing demand for its obesity and diabetes medications.

This landmark investment by Novo Nordisk not only cements North Carolina’s position as a key player in the global pharmaceutical industry but also promises to bring substantial economic benefits to the region through job creation and technological advancement.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE